Shares of Jubilant Ingrevia Ltd. fell by 4% after reaching a day’s high of Rs 688 on 25th October, following muted year-over-year growth in net profit for Q2 FY25. They reported a consolidated profit after tax (PAT) of Rs 59 crore for the quarter ending September 2024, marking a modest 2.6% increase from Rs 57 crore a year ago.

Jubilant Ingrevia’s Q2 FY25 net profit rose 21.1% quarter-over-quarter to Rs 49 crore, compared to the previous quarter.

Consolidated revenue grew 2.5% year-over-year to Rs 1,045 crore, showing a 2% sequential rise.

EBITDA for Q2 FY25 increased by 7% year-over-year to Rs 135 crore, with EBITDA margin expanding to 13% from 12% in Q2 FY24 and Q1 FY25. PAT margin remained stable at 6% year-over-year.

Their revenue and EBITDA growth were supported by higher sales of Pyridine building blocks and Fine Chemicals in the Speciality Chemicals segment and increased prices and volumes of Vitamin B3 in Nutrition & Health Solutions.

Revenue and EBITDA were partially impacted by higher logistics costs due to container shortages and increased shipping expenses from the Red Sea crisis.

At 3:30 PM, the shares of Jubilant Ingrevia closed 4.35% lower at Rs 655 on NSE.

Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!